Skip to main content

Clinical Trials Using Rituximab

Review the clinical trials studying rituximab on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 101-124 of 124

Loncastuximab Tesirine and Rituximab after Stereotactic Radiosurgery for the Treatment of Primary and Secondary Central Nervous System Lymphomas, SOLAR Trial
Status: Active
Location: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia
Status: Active
Location: OHSU Knight Cancer Institute, Portland, Oregon
Intraventricular CARv3-TEAM-E T Cells for the Treatment of Patients with Glioblastoma, INCIPIENT Study
Status: Active
Location: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Donor Blood Stem Cells (Ex Vivo TCR Alpha/Beta and CD19-Depleted Stem Cells) for the Prevention of Graft-versus-Host Disease in Pediatric Patients with Blood Cancer
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Loncastuximab and Roflumilast in Combination with R-CHOP (Lo-RR-CHOP) for the Treatment of High-Risk Diffuse Large B-cell Lymphoma
Status: Active
Location: Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio, Texas
Calaspargase Pegol plus Combination Chemotherapy for the Treatment of Young Adults with Newly Diagnosed Acute Lymphoblastic Leukemia
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
Status: Active
Location: 3 locations
A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL
Status: Active
Location: See ClinicalTrials.gov
A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas
Status: Active
Location: See ClinicalTrials.gov
TCRalpha/beta and CD19+ depleted Hematopoietic Stem Cell Transplant from Closely Matched Unrelated Donors or Haploidentical Related donors for Blood Disorders in Children and Young Adults
Status: Approved
Location: 2 locations
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults with Newly Diagnosed B Acute Lymphoblastic Leukemia
Status: Temporarily Closed to Accrual
Location: 428 locations
Testing CC-486 (Oral Azacitidine) plus the Standard Drug Therapy in Patients 75 years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma
Status: Temporarily Closed to Accrual
Location: 149 locations
Measurable Residual Disease Guided De-Intensification of Bendamustine and Rituximab for the Treatment of Indolent Non-Hodgkin Lymphoma
Status: Temporarily Closed to Accrual
Location: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Status: Temporarily Closed to Accrual
Location: 100 locations
Rituximab and Pembrolizumab with or without Lenalidomide in Treating Patients with Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Ibrutinib and Rituximab in Treating Patients with Relapsed or Refractory Mantle Cell Lymphoma or Older Patients with Newly Diagnosed Mantle Cell Lymphoma
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Zanubrutinib in Combination with R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma
Status: Temporarily Closed to Accrual
Location: 3 locations
Tazemetostat in Combination with Zanubrutinib and Rituximab or Obinutuzumab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia or Follicular Lymphoma, TARZAN Trial
Status: Temporarily Closed to Accrual
Location: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Fludarabine and Cyclophosphamide with or without Rituximab before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Temporarily Closed to Accrual
Location: University of California Davis Comprehensive Cancer Center, Sacramento, California
Real-Time Circulating Tumor Deoxyribonucleic Acid Sequencing to Guide Therapy in Newly Diagnosed Diffuse Large B-Cell Lymphoma, SHORTEN-ctDNA Trial
Status: Active
Location: NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York
Immune Suppression Treatment for People With Sickle Cell Disease or Beta-Thalassemia Who are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Active
Location: 7 locations
Hyperpolarized Carbon C 13 Pyruvate MRI for the Diagnosis of Patients with Primary Central Nervous System Lymphoma
Status: Active
Location: University of California San Francisco, San Francisco, California